Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M. Lee CK, et al. Among authors: angleitner boubenizek l. Br J Cancer. 2011 Oct 11;105(8):1144-50. doi: 10.1038/bjc.2011.364. Epub 2011 Sep 13. Br J Cancer. 2011. PMID: 21915127 Free PMC article.
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study.
Sehouli J, Reinthaller A, Marth C, Reimer D, Reimer T, Stummvoll W, Angleitner-Boubenizek L, Brandt B, Chekerov R. Sehouli J, et al. Among authors: angleitner boubenizek l. Br J Cancer. 2014 Oct 14;111(8):1519-25. doi: 10.1038/bjc.2014.443. Epub 2014 Sep 16. Br J Cancer. 2014. PMID: 25225907 Free PMC article. Clinical Trial.
Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.
Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjólfsdóttir B, Kim JW, Gleeson N, Brotto L, Tu D, Shepherd LE; CX.5 SHAPE investigators; CX.5 SHAPE Investigators. Plante M, et al. N Engl J Med. 2024 Feb 29;390(9):819-829. doi: 10.1056/NEJMoa2308900. N Engl J Med. 2024. PMID: 38416430 Free article. Clinical Trial.
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
Petru E, Angleitner-Boubenizek L, Reinthaller A, Deibl M, Zeimet AG, Volgger B, Stempfl A, Marth C. Petru E, et al. Among authors: angleitner boubenizek l. Gynecol Oncol. 2006 Aug;102(2):226-9. doi: 10.1016/j.ygyno.2005.12.017. Epub 2006 Jan 27. Gynecol Oncol. 2006. PMID: 16443259 Clinical Trial.
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.
Petru E, Reinthaller A, Angleitner-Boubenizek L, Schauer C, Zeimet A, Dirschlmayer W, Medl M, Stummvoll W, Sevelda P, Marth C. Petru E, et al. Among authors: angleitner boubenizek l. Wien Klin Wochenschr. 2010 Nov;122(21-22):649-52. doi: 10.1007/s00508-010-1483-1. Epub 2010 Nov 15. Wien Klin Wochenschr. 2010. PMID: 21072604
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy.
Petru E, Andel J, Angleitner-Boubenizek L, Steger G, Bernhart M, Busch K, Gehmacher O, Hernler T, Kastner U, Lanz-Veit A, Pluschnigg U, Polachova J, Rohde M, Schiller L, Schramböck R, Stangl W, Thödtmann R, Zabernigg A. Petru E, et al. Among authors: angleitner boubenizek l. Wien Med Wochenschr. 2008;158(5-6):169-73. doi: 10.1007/s10354-008-0515-1. Wien Med Wochenschr. 2008. PMID: 18421559
Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.
Petru E, Zeimet AG, Sevelda P, Seifert M, Singer C, Hubalek M, Angleitner-Boubenizek L, Speiser P, Benedicic C, Stummvoll W, Reinthaller A; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO). Petru E, et al. Among authors: angleitner boubenizek l. Wien Klin Wochenschr. 2012 Jun;124(11-12):412-8. doi: 10.1007/s00508-012-0185-2. Epub 2012 Jun 28. Wien Klin Wochenschr. 2012. PMID: 22739650